Brusatol Regulates Ferroptosis of Ovarian Cancer Through the Nrf2/HO-1/NQO1 and AKT/mTOR Double Signaling Pathways
In this study, we demonstrated for the first time through bioinformatics, molecular docking technology, and experimental validation that BRU acts as a novel inducer of ferroptosis in ovarian cancer cells by targeting the Nrf2/HO-1/NQO1 and AKT/mTOR dual signaling pathways, and may have great potential in the treatment of ovarian cancer cells.
Authors
- Jian Hua (ORCID: https://orcid.org/0000-0002-6929-8066)
- Chaoqun Lian (ORCID: https://orcid.org/0000-0003-4914-020X)
- XIAOFU LIAN
- Hongli Liu (ORCID: https://orcid.org/0000-0002-5263-8108)
- Luyao Wang (ORCID: https://orcid.org/0000-0003-1595-6593)
- Jing Zhang (ORCID: https://orcid.org/0000-0002-3694-2548)
- Mengling Hu
Institutions
- Bengbu Medical College (CN)
- First Affiliated Hospital of Bengbu Medical College (CN)
Publication Details
- Journal
- Current Pharmaceutical Design
- Published
- 2025-08-22
- DOI
- https://doi.org/10.2174/0113816128383328250808123933
- Citations
- 2
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 1.87